ZYME Zymeworks Inc.

25.57
-0.27  -1%
Previous Close 25.84
Open 25.91
Price To Book 3.12
Market Cap 1,003,876,615
Shares 39,259,938
Volume 21,486
Short Ratio 3.41
Av. Daily Volume 244,637

NewsSee all news

  1. Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds

  2. Zymeworks to Participate in Upcoming Investor Conferences

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences. Wells Fargo

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 updated data due at ESMO September 28, 2019, 5:36pm CEST. Phase 2 trial initiation announced April 15, 2019.
ZW25
HER2-expressing Cancers - ovarian, breast, gastric
Phase 1 data due 2H 2019.
ZW49
HER2-Expressing Cancers

Latest News

  1. Zymeworks Announces New Chair of Board of Directors and Voluntary Delisting from the TSX

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that Lota Zoth has been appointed as its Chair of the Board of Directors. Ms. Zoth succeeds

  2. Zymeworks to Participate in Upcoming Investor Conferences

    Zymeworks Inc. (TSX:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that management will participate in three upcoming investor conferences. Wells Fargo